Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection.

Denisova OV, Kakkola L, Feng L, Stenman J, Nagaraj A, Lampe J, Yadav B, Aittokallio T, Kaukinen P, Ahola T, Kuivanen S, Vapalahti O, Kantele A, Tynell J, Julkunen I, Kallio-Kokko H, Paavilainen H, Hukkanen V, Elliott RM, De Brabander JK, Saelens X, Kainov DE.

J Biol Chem. 2012 Oct 12;287(42):35324-32. doi: 10.1074/jbc.M112.392142. Epub 2012 Aug 21.

2.

Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine.

Söderholm S, Anastasina M, Islam MM, Tynell J, Poranen MM, Bamford DH, Stenman J, Julkunen I, Šaulienė I, De Brabander JK, Matikainen S, Nyman TA, Saelens X, Kainov D.

Antiviral Res. 2016 Feb;126:69-80. doi: 10.1016/j.antiviral.2015.12.011. Epub 2015 Dec 29.

3.

Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika virus infection in vitro and differentially affect cellular signaling, transcription and metabolism.

Kuivanen S, Bespalov MM, Nandania J, Ianevski A, Velagapudi V, De Brabander JK, Kainov DE, Vapalahti O.

Antiviral Res. 2017 Mar;139:117-128. doi: 10.1016/j.antiviral.2016.12.022. Epub 2016 Dec 31.

PMID:
28049006
4.

Inhibition of influenza A virus infection in vitro by saliphenylhalamide-loaded porous silicon nanoparticles.

Bimbo LM, Denisova OV, Mäkilä E, Kaasalainen M, De Brabander JK, Hirvonen J, Salonen J, Kakkola L, Kainov D, Santos HA.

ACS Nano. 2013 Aug 27;7(8):6884-93. doi: 10.1021/nn402062f. Epub 2013 Aug 1.

PMID:
23889734
5.

[In vitro activity of Ingavirin against influenza virus A (H3N2)].

Loginova SIa, Borisevich SV, Semenova IV, Maksimov VA, Bondarev VP, Nebol'sin VE.

Antibiot Khimioter. 2009;54(9-10):23-6. Russian.

PMID:
20415259
6.

Receptor tyrosine kinase inhibitors that block replication of influenza a and other viruses.

Kumar N, Sharma NR, Ly H, Parslow TG, Liang Y.

Antimicrob Agents Chemother. 2011 Dec;55(12):5553-9. doi: 10.1128/AAC.00725-11. Epub 2011 Sep 19.

7.

Antiviral activity of novel oseltamivir derivatives against some influenza virus strains.

Kocik J, Kołodziej M, Joniec J, Kwiatek M, Bartoszcze M.

Acta Biochim Pol. 2014;61(3):509-13. Epub 2014 Sep 12.

8.

The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections.

Müller KH, Kainov DE, El Bakkouri K, Saelens X, De Brabander JK, Kittel C, Samm E, Muller CP.

Br J Pharmacol. 2011 Sep;164(2):344-57. doi: 10.1111/j.1476-5381.2011.01346.x.

9.

Antiviral Activity of the Human Cathelicidin, LL-37, and Derived Peptides on Seasonal and Pandemic Influenza A Viruses.

Tripathi S, Wang G, White M, Qi L, Taubenberger J, Hartshorn KL.

PLoS One. 2015 Apr 24;10(4):e0124706. doi: 10.1371/journal.pone.0124706. eCollection 2015.

10.

Pyrazole compound BPR1P0034 with potent and selective anti-influenza virus activity.

Shih SR, Chu TY, Reddy GR, Tseng SN, Chen HL, Tang WF, Wu MS, Yeh JY, Chao YS, Hsu JT, Hsieh HP, Horng JT.

J Biomed Sci. 2010 Feb 23;17:13. doi: 10.1186/1423-0127-17-13.

11.

Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses.

Di Trani L, Savarino A, Campitelli L, Norelli S, Puzelli S, D'Ostilio D, Vignolo E, Donatelli I, Cassone A.

Virol J. 2007 May 3;4:39.

12.

Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).

Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z, Bornmann W, Kantarjian H, Viallet J, Samudio I, Andreeff M.

Cancer Res. 2008 May 1;68(9):3413-20. doi: 10.1158/0008-5472.CAN-07-1919.

13.

Antiviral resistance in influenza viruses--implications for management and pandemic response.

Hayden FG.

N Engl J Med. 2006 Feb 23;354(8):785-8. No abstract available.

14.

Phosphatidylglycerol suppresses influenza A virus infection.

Numata M, Kandasamy P, Nagashima Y, Posey J, Hartshorn K, Woodland D, Voelker DR.

Am J Respir Cell Mol Biol. 2012 Apr;46(4):479-87. doi: 10.1165/rcmb.2011-0194OC. Epub 2011 Nov 3.

15.

A Nucleolar Protein, Ribosomal RNA Processing 1 Homolog B (RRP1B), Enhances the Recruitment of Cellular mRNA in Influenza Virus Transcription.

Su WC, Hsu SF, Lee YY, Jeng KS, Lai MM.

J Virol. 2015 Nov;89(22):11245-55. doi: 10.1128/JVI.01487-15. Epub 2015 Aug 26.

16.
17.

Inhibition of influenza virus replication by constrained peptides targeting nucleoprotein.

Jiang H, Xu Y, Li L, Weng L, Wang Q, Zhang S, Jia B, Hu H, He Y, Jacob Y, Toyoda T.

Antivir Chem Chemother. 2011 Nov 17;22(3):119-30. doi: 10.3851/IMP1902.

PMID:
22095520
18.
19.

2'-fluoro-2'-deoxycytidine inhibits Borna disease virus replication and spread.

Bajramovic JJ, Volmer R, Syan S, Pochet S, Gonzalez-Dunia D.

Antimicrob Agents Chemother. 2004 Apr;48(4):1422-5.

20.

Human H-ficolin inhibits replication of seasonal and pandemic influenza A viruses.

Verma A, White M, Vathipadiekal V, Tripathi S, Mbianda J, Ieong M, Qi L, Taubenberger JK, Takahashi K, Jensenius JC, Thiel S, Hartshorn KL.

J Immunol. 2012 Sep 1;189(5):2478-87. doi: 10.4049/jimmunol.1103786. Epub 2012 Jul 30.

Supplemental Content

Support Center